Abstract
Hydroxypropyl methyl cellulose, HPMC, a hydrophilic polymer, is widely used for the development of extended release hydrophilic matrices and it is also considered as a good contender for the fabrication of 3D printing of matrix tablets. It is often combined with plasticisers to enable extrusion. The aim of the current project was to develop plasticizer-free 3D printed hydrophilic matrices using drug loaded filaments prepared via HME to achieve an in vitro (swelling, erosion and drug release) and in vivo (drug absorption) performance which is analogous to hydrophilic matrix tablets developed through conventional approaches. Additionally, the morphology of the printed tablets was studied using quantitative 3D surface texture studies and the porosity calculated. Filaments were produced successfully and used to produce matrix tablets with acceptable drug loading (95–105%), mechanical and surface texture properties regardless of the employed HPMC grade. The viscosity of HPMC had a discernible impact on the swelling, erosion, HPMC dissolution, drug release and pharmacokinetic findings. The highest viscosity grade (K100M) results in higher degree of swelling, decreased HPMC dissolution, low matrix erosion, decreased drug release and extended drug absorption profile. Overall, this study demonstrated that the drug loaded (glipizide) filaments and matrix tablets of medium to high viscosity grades of HPMC, without the aid of plasticisers, can be successfully prepared. Furthermore, the in vitro and in vivo studies have revealed the successful fabrication of extended release matrices.
Highlights
Pharmaceutical industries utilise well established methods for the fabrication of tablets with predetermined dose, size and shape [1]
In order to address these challenges, we proposed to develop plasticizer-free 3D printed hydrophilic matrices using drug loaded filaments prepared via hot melt extrusion (HME) to achieve an in vitro and in vivo performance which is analogous to hydrophilic matrix tablets developed through conventional approaches
The current study has successfully demonstrated the fabrication of HPMC: Glipizide filaments and 3D printed matrix tablets without the addition of plasticiser
Summary
Pharmaceutical industries utilise well established methods for the fabrication of tablets with predetermined dose, size and shape [1]. Polymers 2019, 11, 1095 forms, with a variety of strengths, such as three dimensional (3D) printing, is required to accomplish the personalised therapeutic needs of individuals [5]. This technology has enabled cost-effective fabrication of individualised dosage forms and has potential to develop personalised pharmaceutical products [3,5]. FDM is one of the most common with significant potential for achieving personalised dosage forms as it can be used to deposit a large range of doses and multiple drugs into solid dosage forms of almost any shape [8]. Research has focused on using already established materials for filament production, there are no commercial products available yet [6,11,12,13,14,15,16,17,18,19]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
